Vivos Therapeutics Reports Widened Net Loss, Negative Equity, and Going Concern Warning Amidst Nasdaq Delisting Risk
VVOS sits 25% above its 52-week low of $1.085 on elevated volume (2.3× avg).
Summary
Vivos Therapeutics reported a significantly wider net loss and negative stockholders' equity in its 2025 annual report, triggering a 'going concern' warning and immediate Nasdaq non-compliance, despite strategic acquisitions and recent capital raises.
Key Events · Earnings and Guidance · VVOS
-
Net Loss Nearly Doubles in 2025
The company reported a net loss of $21.2 million for the year ended December 31, 2025, a significant increase from $11.1 million in 2024, indicating a worsening financial performance.
-
Auditor Issues 'Going Concern' Warning
The independent registered public accounting firm included an explanatory paragraph in its report, citing recurring losses from operations and insufficient cash to fund objectives, raising substantial doubt about the company's ability to continue as a going concern.
-
Negative Stockholders' Equity Triggers Nasdaq Non-Compliance
Vivos Therapeutics reported a stockholders' deficit of $1.49 million as of December 31, 2025, down from $7.95 million in equity in 2024. This puts the company out of compliance with Nasdaq's $2.5 million minimum equity requirement, leading to delisting proceedings.
-
Strategic Pivot and SCN Acquisition Face Integration Challenges
The company's shift to a medical-provider focused model, including the June 2025 acquisition of The Sleep Center of Nevada (SCN) for $8.7 million, is experiencing difficulties such as patient demand exceeding capacity, staffing issues, and delays in insurance credentialing, impacting expected revenue growth.
Analysis · VVOS · Industrial Applications And Services
Vivos Therapeutics' 2025 annual report reveals a significant deterioration in its financial health, marked by a substantial increase in net loss and a critical 'going concern' warning from its auditor. The company's net loss nearly doubled to $21.2 million in 2025 from $11.1 million in 2024, with cash used in operations also increasing. Critically, Vivos Therapeutics now has negative stockholders' equity of $1.49 million, placing it out of compliance with Nasdaq's minimum listing requirements and exposing it to a high risk of delisting. While the company is actively pursuing a strategic pivot to a medical-provider focused model, including the acquisition of The Sleep Center of Nevada (SCN), and has secured some recent capital through warrant exercises and private placements, these efforts have not yet stabilized its financial position. The challenges in integrating SCN and securing insurance reimbursement further complicate its path to profitability. Investors face significant uncertainty regarding the company's ability to secure sufficient long-term funding and achieve sustainable operations.
At the time of this filing, VVOS was trading at $1.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $1.09 to $7.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.